Table 4 LC3/β-actin, p-ERK/ERK and Beclin 1/β-actin concentrations against the tested trials.

From: In vitro and in vivo anti-colorectal cancer effect of the newly synthesized sericin/propolis/fluorouracil nanoplatform through modulation of PI3K/AKT/mTOR pathway

Tested trials

LC3/β-actin

p-ERK/ERK

Beclin 1/β-actin

Caco-2 control

0.2525820636 ± 0.04

1.63024032 ± 0.04

0.2617343287 ± 0.02

4

1.070611277 ± 0.03

1.008833341 ± 0.05

0.6348830018 ± 0.01

15

1.464358362 ± 0.02

0.599475983 ± 0.02

1.612231361 ± 0.03

16

0.965806203 ± 0.02

1.179297501 ± 0.03

1.125361202 ± 0.02

20

1.07405147 ± 0.03

0.678089835 ± 0.02

1.664988302 ± 0.01

  1. Data are represented as the mean ± SD.
Back to article page